HOME >> MEDICINE >> NEWS
New kidney disease drug saves lives at low cost

A recent study has found that sevelamer (Renagel) is having a positive long term clinical and economic effect when used on hemodialysis patients. This study, undertaken by the Caro Research Institute in Concord, MA and published in Value in Health, examined the long-term consequences associated with one year of sevelamer use.

"The safety and efficacy of sevelamer and its ability to attenuate the progression of calcification have been well documented in a seminal clinical study, but the study was not designed to assess the longer-term implications," says Krista Huybrechts who led the study.

Huybrechts' team developed a simulation model based on the best available evidence to date, and estimated that in the long-term, patients on sevelamer have a 12% lower cardiovascular risk than those on calcium binders. The cost savings accrued due to avoiding cardiovascular events largely offset the higher drug cost, leading to a very favorable cost-effectiveness ratio of about $2,200 of increased cost per life year gained.

The results of this study now allow health policy makers and payers to understand the value of sevelamer in the long-term where it could not have been done from the clinical study alone.

Close to 500,000 Americans suffer from Stage V chronic kidney disease (CKD) and have a 10-20 times higher risk of cardiovascular mortality than the general population.


'"/>

Contact: Kathleen Mulcahy
kmulcahy@bos.blackwellpublishing.com
781-388-8348
Blackwell Publishing Ltd.
30-Nov-2005


Page: 1

Related medicine news :

1. 1 of 2 pediatric kidney disease research centers in world established
2. Indiana University Imaging Center receives $6M grant for kidney research
3. Obesity linked to hyperparathyroidism in chronic kidney disease
4. Study shows radiofrequency ablation highly effective in treating kidney tumors
5. Mouse model points to possible new strategy for treating rare muscle disease, kidney disorders
6. Quality versus quantity -- transforming kidney transplant policy
7. ACE inhibitors help preserve kidney function in IgA nephropathy
8. Treatment of kidney condition requires an individualized approach
9. Study evaluates why blacks do not successfully donate kidneys
10. Cause of gender differences in blood pressure, kidney damage under study
11. Who receives a kidney transplant first?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New kidney disease drug saves lives low cost

(Date:5/18/2013)... COOLA, British Columbia (PRWEB) May 19, 2013 ... to Cooking” (published by iUniverse) , author Janet Hall Svisdahl’s ... delectable world recipes sure to make even the pickiest ... living peacefully, pleasurably and prayerfully,” she explains. , Found ... Spirit” are a wide range of delicious recipes, from fast ...
(Date:5/18/2013)... 2013) The American Gastroenterological Association (AGA) Research ... scholars. This year,s honorees are outstanding young gastroenterologists ... related areas, and with this award, their research ... researchers are the future of our field. AGA ... paving the way for promising research developments and ...
(Date:5/18/2013)... Thompson HealthDay Reporter , , FRIDAY, May 17 ... the latest edition of what is considered the "bible" ... many changes continues. "This is unprecedented, the amount ... Lieberman, president-elect of the American Psychiatric Association (APA). "It,s ... it is. You have to evaluate it and then ...
(Date:5/18/2013)... Orlando, FL (May 18, 2013) The use ... for a colonoscopy, according to new research presented ... process, which begins days in advance of the ... preparation medication to be taken at strict intervals. ... for doctors to see cancer and precancerous polyps ...
(Date:5/18/2013)... 18, 2013 Assisted living and ... to safety and comfort of their residents. Systems ... clients with an effective and cost-efficient solution – ... an integrated, turnkey communications solution that helps nurses ... residents independence and privacy. , The VisionLink ...
Breaking Medicine News(10 mins):Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:New smartphone application improves colonoscopy preparation 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3
(Date:5/17/2013)... 2013 Sinovac Biotech Ltd. (Nasdaq: SVA ... , today announced that it will release its unaudited ... before market on Tuesday, May 28, 2013.  The Company will ... 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m. China ... an update on recent corporate developments. To access ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... and Research (A*STAR) and Switzerland,s Cytos ... been dosed in a Phase 1 clinical trial with their ... virus-like particle (VLP) technology. In this first Phase 1 clinical ... and its potential to protect against H1N1 influenza infection will ...
(Date:5/16/2013)... N.J. , May 16, 2013  PTC Therapeutics, ... statement on Form S-1 with the U.S. Securities and ... offering of its common stock. The number of shares ... offering have not been determined. (Logo:  ... Suisse are acting as joint book-running managers for the ...
Breaking Medicine Technology:Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
Cached News: